AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1579267
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of folate daily around the time of conception
Trial: 2870808
Drug: Acetaminophen (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (650 mg) and Pentazocine (25 mg)
Trial: 2870808
Drug: Acetaminophen (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (300 mg) and Codeine (30 mg)
Trial: 2870808
Drug: Acetaminophen (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (650 mg) and Propoxyphene Napsylate (100 mg)
Trial: 3784917
Drug: High-dose oestrogen-progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oestrogen-progestogen therapy
Trial: 3784917
Drug: Combined oestrogen-progestogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oestrogen-progestogen therapy (all doses)
Trial: 3784917
Drug: All treated
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treated groups (including high-dose)
Trial: 3784917
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in daily creatinine excretion
Trial: 28237253
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of hyaluronic acid (HA)
Trial: 26247661
Drug: Iodine supplementation
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine supplementation (150 μg/day)
Trial: 21110180
Drug: Aidi Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aidi Injection (ADI) 100 mL added to 500 mL of 5% glucose injection, administered intravenously once daily for 14 days before each course of chemotherapy (total 28 days).
Trial: 11001887
Drug: 5‐aza‐2'‐deoxycytidine (5‐aza‐CdR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐aza‐2'‐deoxycytidine (5‐aza‐CdR, decitabine) at doses ranging from 0.15 to 0.30 mg/kg given 5 days a week for 2 weeks
Trial: 8482458
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa treatment
Trial: 24918560
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate (BT) 0.5% gel
Trial: 18261195
Drug: Aripiprazole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 2.5 mg
Trial: 15721800
Drug: Cortisol administered
RxNorm normalized name: cortisol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol administered before recall testing
Trial: 12641876
Drug: Treatment recommendations
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment recommendations based on evidence from CKD populations or general population
Trial: 11006055
Drug: Soymilk supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soymilk supplementation (400 mL daily for two menstrual cycles)
Trial: 8784280
Drug: Eutectic lidocaine/prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eutectic lidocaine/prilocaine 5% cream under occlusive dressing (Tegaderm)
Trial: 8784280
Drug: Eutectic lidocaine/prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eutectic lidocaine/prilocaine 5% patch
Trial: 1732427
Drug: Cisplatin (CP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CP) 100 mg/m2 and Fluorouracil (5-FU) 1 g/m2 x 4
Trial: 1732427
Drug: Cisplatin (CP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CP) and Fluorouracil (5-FU) combination
Trial: 6365809
Drug: sfericase (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sfericase (6 tablets/day)
Trial: 6365809
Drug: sfericase (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sfericase (2 tablets, 3X/day)
Trial: 30293937
Drug: Lipid-lowering drug
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drug treatment (LLT)
Trial: 30293937
Drug: Lipid-lowering drug
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drug treatment (LLT) in highest risk tertile
Trial: 23099111
Drug: Behavioral Weight-Loss-Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Weight-Loss-Treatment (BWLT)
Trial: 17563981
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy plus basic therapy
Trial: 11549652
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg oral conjugated E
Trial: 11549652
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg droloxifene
Trial: 28224367
Drug: MOC31PE immunotoxin
RxNorm normalized name: hepatitis B immunoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOC31PE immunotoxin administered intraperitoneally as a single dose after CRS-HIPEC with Mitomycin C
Trial: 25319807
Drug: Adjuvant interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant interferon alfa-2b (IFN-α) therapy for 12 or 24 months
Trial: 25128049
Drug: Sensor-augmented insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensor-augmented insulin pump therapy with Low Glucose Suspend (LGS)
Trial: 25128049
Drug: Standard pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pump therapy with self-monitoring of blood glucose
Trial: 25128049
Drug: Sensor-augmented insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensor-augmented insulin pump therapy with LGS
Trial: 17560730
Drug: Mirtazapine monotherapy
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine monotherapy (n=13)
Trial: 17560730
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with mirtazapine and lithium (n=13)
Trial: 17560730
Drug: Mirtazapine monotherapy
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine monotherapy (n=10)
Trial: 17560730
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with mirtazapine and carbamazepine (n=10)
Trial: 10036794
Drug: 6% medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% medium molecular weight hydroxyethylstarch solution made of potato (K)
Trial: 10036794
Drug: 6% medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% medium molecular weight hydroxyethylstarch solution made of corn (M)
Trial: 25193374
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioural therapy (iCBT)
Trial: 31638341
Drug: Cabazitaxel (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (20 mg/m2) i.v. every 3 weeks with prednisolone 10 mg daily orally, for a maximum of 10 cycles
Trial: 26646596
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional therapies and care)
Trial: 21195962
Drug: Intravenous conscious
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous conscious sedation
Trial: 21195962
Drug: Oral analgesia
RxNorm normalized name: P-A-C Analgesic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesia
Trial: 17156179
Drug: Vouchers for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vouchers for 6 months of methadone treatment
Trial: 30860410
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both interventions
Trial: 9849834
Drug: Selective digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective digestive decontamination (SDD) with triple therapy of colimycin, tobramycin, and nystatin administered orally or via nasogastric tube every 6 hours, plus oropharyngeal decontamination with hexitidine for patients with mechanical ventilation or immune-depression.
Trial: 17146635
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no SDD treatment)
Trial: 8044943
Drug: recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant tissue-type plasminogen activator (rTPA) therapy
Trial: 30571923
Drug: Standardized rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized rehabilitation therapy
Trial: 21477197
Drug: Combination training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination training (non-verbal reasoning + working memory)
Trial: 11938856
Drug: DMPS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPS plus Gandou tablet
Trial: 8137583
Drug: Intraperitoneal distribution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal distribution imaging (IDI) using 1000 ml of normal saline and 1 mCi of Tc‐99m SC
Trial: 30829771
Drug: Repeated onabotulinumtoxinA
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated onabotulinumtoxinA 64 U treatment in Period 2
Trial: 30643391
Drug: Quesero XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quesero XR 200 mg
Trial: 30643391
Drug: Seroquel XR
RxNorm normalized name: Seroquel XR
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Seroquel XR 200 mg
Trial: 28366518
Drug: Conventional daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional daily gonadotropins (recombinant FSH and highly purified human menopausal gonadotrophin)
Trial: 21585690
Drug: Decision aids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision aids for mastectomy versus breast-conserving therapy
Trial: 19450071
Drug: Radiation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation treatment schedules
Trial: 17008803
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with twice-daily IFN-beta (3X2=6 million units/day)
Trial: 17008803
Drug: Consensus interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consensus interferon monotherapy
Trial: 17008803
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with twice-daily IFN-beta
Trial: 12933575
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m2 with induction chemotherapy (DAT, DA, or FLAG-Ida)
Trial: 12933575
Drug: GO 3
RxNorm normalized name: RESERVOIR,VGO 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GO 3 mg/m2 with consolidation (MACE or HidAC)
Trial: 24002913
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 100 mg
Trial: 31233281
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg monotherapy
Trial: 21351291
Drug: Multiple treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple treatments including Chinese herbs, acupuncture, and massage therapy
Trial: 12233895
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (omeprazole 20 mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid for 7 days)
Trial: 12233895
Drug: Omeprazole alone
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole alone (20 mg once daily)
Trial: 12233895
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori negative patients (omeprazole 20 mg once daily)
Trial: 10081035
Drug: Fenofibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (200 mg daily for 2 weeks)
Trial: 7752627
Drug: Alcohol session
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol session (0.625 g/kg body weight of 80-proof ethyl alcohol)
Trial: 2268634
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of fluoride varnish (Duraphat) on cavity walls
Trial: 6780021
Drug: Real bilateral
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real bilateral electric convulsion therapy
Trial: 6780021
Drug: Simulated bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated bilateral electric convulsion therapy
Trial: 6780021
Drug: Real bilateral
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real bilateral electric convulsion therapy after switching from simulated treatment
Trial: 31815655
Drug: Chinese pediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese pediatric Tuina (15-25 min treatment once per day for 3 consecutive days)
Trial: 31815655
Drug: Sham pediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham pediatric Tuina (15-25 min treatment once per day for 3 consecutive days)
Trial: 28209636
Drug: Sodium-restricted diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-restricted diet (target <2 g sodium per day)
Trial: 22691430
Drug: DTaP₅-IPV-Hib vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP₅-IPV-Hib vaccine
Trial: 19556533
Drug: Antiplatelet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet treatment (specifics not provided)
Trial: 15632895
Drug: Glucose-Insulin-Potassium (GIK)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-Insulin-Potassium (GIK) intravenous infusion for 24 hours
Trial: 15632895
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (Reviparin) injection twice daily for 7 days
Trial: 15632895
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection twice daily for 7 days
Trial: 7524736
Drug: nIFN alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nIFN alpha (3 MU) intramuscularly three times weekly
Trial: 7524736
Drug: nIFN alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nIFN alpha (3 MU) intramuscularly three times weekly plus 6-methyl-prednisolone (16 mg/d orally on non-IFN days)
Trial: 7524736
Drug: 6-methyl-prednisolone (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-methyl-prednisolone (16 mg/d orally) only
Trial: 23582353
Drug: AREDS formulation
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AREDS formulation (high-dose antioxidants C, E, β-carotene, and zinc)
Trial: 18180976
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg monthly oral ibandronate
Trial: 18180976
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of ibandronate
Trial: 14624185
Drug: Sertraline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline and CBT
Trial: 10174220
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of photographic and written information
Trial: 3034538
Drug: PDD 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDD 10 mg per day X 10, every 3 weeks (hepatic arterial perfusion)
Trial: 3034538
Drug: 5‐Fu 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐Fu 250 mg per day X 4, every week and thio‐tepa (TSPA) 10 mg, twice a week (hepatic arterial perfusion)
Trial: 3034538
Drug: PDD 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDD 20 mg per day X 5, every 3 weeks (intravenous chemotherapy)
Trial: 3034538
Drug: 5‐Fu 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐Fu 500 mg and TSPA 10 mg, twice a week (intravenous chemotherapy)
Trial: 3034538
Drug: Intravenous PDD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PDD
Trial: 3034538
Drug: Intravenous control
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous control group
Trial: 26667118
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive approach based on atraumatic restorative treatment (ART) procedures
Trial: 23569175
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (GLA)
Trial: 18093252
Drug: Coracten (encapsulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coracten (encapsulated mini-tablet)
Trial: 18093252
Drug: N-GITS (30-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-GITS (30-mg osmotic, constant-release nifedipine gastrointestinal therapeutic system)
Trial: 10475139
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg oral budesonide
Trial: 8757005
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) nasal spray (1 mg plus optional 1 mg)
Trial: 7106687
Drug: Phlebodril (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebodril (fixed combination)
Trial: 24982780
Drug: Trospium 60
RxNorm normalized name: trospium 60 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospium 60 mg/day and Solifenacin 20 mg/day during two cycles (1.5 and 1 month with one month interval)
Trial: 24982780
Drug: Trospium 60
RxNorm normalized name: trospium 60 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospium 60 mg/day and Solifenacin 20 mg/day during one cycle therapy
Trial: 19920098
Drug: Adenovirus/prostate-specific antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus/prostate-specific antigen (PSA) vaccine
Trial: 17214953
Drug: Concurrent verbal
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent verbal protocol method
Trial: 17214953
Drug: Quantitative analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative analysis of concurrent reports
Trial: 7658483
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g calcium
Trial: 7658483
Drug: 2.0 g
RxNorm normalized name: Fifty50 2.0 Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g calcium
Trial: 21864622
Drug: 7.5-mcg or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5-mcg or 30-mcg of hemagglutinin intramuscularly
Trial: 19644190
Drug: Lercamen (lercadipine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercamen (lercadipine) 10-20 mg
Trial: 17905575
Drug: Budesonide/formoterol 160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 160/4.5 microg two inhalations twice daily and as needed
Trial: 17905575
Drug: Salmeterol/fluticasone 50/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone 50/500 microg one inhalation twice daily plus terbutaline as needed
Trial: 15388510
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg at week 0, 2, and 6)
Trial: 9787699
Drug: High iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High iron weaning diet (8.2 +/‐ 2.9 mg/day)
Trial: 9787699
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group weaning diet (5.2 +/‐ 3.4 mg/day)
Trial: 8925517
Drug: Weekly wine
RxNorm normalized name: Wine grape
DrugBank: Wine grape (DB10634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly wine consumption
Trial: 2673511
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol (15 mg) followed by oral metoprolol (200 mg daily for 15 days)
Trial: 25417843
Drug: Trivia Game
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trivia Game (treatment group)
Trial: 22047559
Drug: Anti-inhibitor coagulant
RxNorm normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inhibitor coagulant complex (AICC) prophylaxis at a target dose of 85 U/kg (±15%) on 3 nonconsecutive days per week